FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250331164> ?p ?o ?g. }

• W4250331164 endingPage "1130" @default.
• W4250331164 startingPage "1129" @default.
• W4250331164 abstract "We thank Drs Zhang and Yang for their comments. In their letter, Drs Zhang and Yang raised the possibility that the cardiotoxicity seen in our cohort may have been predominantly due to the effect of anthracyclines rather than trastuzumab. They cited three studies; a meta-analysis of 6 randomized control trials by Antonis Valachis et al. which showed a low rate of severe cardiac toxicity in patients treated with trastuzumab alone1Valachis A. Nearchou A. Polyzos N.P. Lind P. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.Int J Cancer. 2013; 133: 2245-2252Crossref PubMed Scopus (43) Google Scholar; a study by de Azambuja et al. which demonstrated that the cardiotoxicity induced by trastuzumab was reversible2de Azambuja E. Bedard P.L. Suter T. Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?.Target Oncol. 2009; 4: 77-88Crossref PubMed Scopus (93) Google Scholar; and a study by Adamo et al. which reported that trastuzumab-based treatments were well-tolerated in a small cohort of 51 elderly patients > 70 years old with adverse events that were deemed only mild to moderate in severity3Adamo V. Ricciardi G.R. Adamo B. et al.The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population.Oncology. 2014; 86: 16-21Crossref PubMed Scopus (28) Google Scholar; to support their argument that trastuzumab caused very limited cardiotoxicity. In response we would like to highlight a number of points. Firstly, we agree with Drs Zhang and Yang that it is hard to differentiate the effect of anthracycline from trastuzumab since both agents can cause cardiotoxicity independently. Used in combination, both these agents have a synergistic effect. However, just as Drs Zhang and Yang highlighted studies supporting limited cardiotoxicity with trastuzumab, there is also evidence indicating the contrary. Telli et al report that up to 4% of patients enrolled in adjuvant trastuzumab trials experienced severe CHF during treatment and point out that despite early cessation of trastuzumab, a large number of patients in these trials experienced some form of cardiotoxicity that ultimately required discontinuation of trastuzumab.4Telli M.L. Hunt S.A. Carlson R.W. Guardino A.E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.J Clin Oncol. 2007; 25: 3525-3533Crossref PubMed Scopus (340) Google Scholar They also highlighted that approximately 14% of patients in the National Surgical Adjuvant Breast and Bowel Project Protocol B-31 (NSABP B-31) trial had trastuzumab discontinued because of asymptomatic decreases in left ventricular ejection fraction (LVEF).5Perez E.A. Romond E.H. Suman V.J. et al.Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.J Clin Oncol. 2011; 29: 3366-3373Crossref PubMed Scopus (610) Google Scholar Follow-up cardiac evaluations of patients diagnosed with any degree of cardiotoxicity in the NSABP B-31 trial documented that a clinically significant proportion of patients had sustained decrements in their LVEF to less than 50%. There is also recent data from animal studies, which report microscopic irreversible damage to the myocardium from trastuzumab.6Tan T.C. Bouras S. Sawaya H. et al.Time trends of left ventricular ejection fraction and myocardial deformation indices in a cohort of women with breast cancer treated with anthracyclines, taxanes, and trastuzumab.J Am Soc of Echocardiogr. 2015; 28: 509-514Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar Secondly, many of the trials that report minimal long-term cardiotoxic effects of trastuzumab are comprised of breast cancer patients who were treated with anthracyclines prior to initiating therapy with trastuzumab. As a consequence, many of these studies reporting the incidence and prevalence of trastuzumab cardiotoxicity have inherent selection bias particularly since an estimated 2–8% of patients are excluded from clinical trials with trastuzumab due to the development of cardiomyopathy or cardiac symptoms after completing anthracycline therapy.7Francis S.A. Cheng S. Arteaga C.L. Moslehi J. Heart failure and breast cancer therapies: moving towards personalized risk assessment.J Am Heart Assoc. 2014; 3: e000780Crossref Scopus (15) Google Scholar Finally, a more compounding and wider problem is that the reported incidence and prevalence of cardiotoxicity varies greatly as comprehensive analysis of published data on cardiotoxicity is difficult to perform and frequently inadequate because oncology trials vary widely in their methods and definitions of cardiotoxicity. Many oncology trials, including the three that were cited by Drs Zhang and Yang, define cardiotoxicity as a significant drop in left ventricular ejection fraction during treatment with chemotherapy or clinical symptoms of heart failure. Despite the widespread use and acceptance of LVEF as the parameter to monitor anthracycline-induced cardiotoxicity, there is no consensus as to what decrease in or absolute value of LVEF constitutes cardiotoxicity. Evidence also indicates that both clinical symptoms and LVEF lack sensitivity as measures of cardiotoxicity. LVEF is often preserved even though cardiomyocyte damage is proven on biopsy or biomarkers.8Ewer M.S. Ali M.K. Mackay B. et al.A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.J Clin Oncol. 1984; 2: 112-117PubMed Google Scholar Additionally, changes in LVEF have been hypothesized to only occur late in the progression of the disease, after compensatory mechanisms are exhausted. Hence, patients treated with trastuzumab alone (without anthracyclines), who do not meet the classic definition of cardiotoxicity based on a decrease in LVEF or clinical symptoms, may still have subclinical cardiotoxicity that is not detected by these moderately sensitive indices. Studies employing newer technologies such as speckle tracking echocardiography (STE) to measure myocardial deformation (strain) and deformation rate (strain rate) have demonstrated the feasibility of early detection of subclinical LV systolic dysfunction during chemotherapy by detecting abnormalities of regional function that do not result in decreased global LV ejection fraction.9D'Hooge J. Heimdal A. Jamal F. et al.Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations.Eur J of Echocardiogr. 2000; 1: 154-170Crossref PubMed Scopus (867) Google Scholar, 10Mor-Avi V. Lang R.M. Badano L.P. et al.Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography.J Am Soc of Echocardiogr. 2011; 24: 277-313Abstract Full Text Full Text PDF PubMed Scopus (912) Google Scholar The decreases in longitudinal strain and strain rate seen in our cohort at the end of treatment, whether they are due to anthracyclines, trastuzumab or a combination of both, were consistent with other studies of patients treated with anthracyclines and trastuzumab. We also report that these decreases persisted two years after cessation of treatment in our cohort. The significance of the sustained decreases in strain and strain rate observed in our study even after a significant time following cessation of treatment, and significant changes in LV dimensions (though small), which have not previously been reported in the adult population, suggest persistent damage from chemotherapy. Ultimately, the value of changes in echo parameters of LV systolic function in predicting subsequent symptomatic heart failure and the significance of this lack of recovery in all three parameters in predicting future heart failure is still unknown due to a paucity of studies. We agree with Drs Zhang and Yang that larger multi-center studies are clearly needed to test the impact of these decreases in LV function parameters on symptoms, morbidity and mortality. Does Trastuzumab Cause Cardiotoxicity in the Treatment of Patients with Breast Cancer?Journal of the American Society of EchocardiographyVol. 28Issue 9PreviewWe commend Tan et al.1 on their excellent article, “Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.” The authors assessed the cardiotoxicity of trastuzumab, anthracyclines, and taxanes in patients with breast cancer and drew the conclusion that trastuzumab as monotherapy or as part of combination therapy with anthracyclines caused irreversible cardiac damage in their patients. Full-Text PDF" @default.
• W4250331164 created "2022-05-12" @default.
• W4250331164 creator A5043760436 @default.
• W4250331164 creator A5076351586 @default.
• W4250331164 date "2015-09-01" @default.
• W4250331164 modified "2023-10-16" @default.
• W4250331164 title "Author’s Reply" @default.
• W4250331164 doi "https://doi.org/10.1016/j.echo.2015.07.024" @default.
• W4250331164 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26354553" @default.
• W4250331164 hasPublicationYear "2015" @default.
• W4250331164 type Work @default.
• W4250331164 citedByCount "0" @default.
• W4250331164 crossrefType "journal-article" @default.
• W4250331164 hasAuthorship W4250331164A5043760436 @default.
• W4250331164 hasAuthorship W4250331164A5076351586 @default.
• W4250331164 hasBestOaLocation W42503311641 @default.
• W4250331164 hasConcept C71924100 @default.
• W4250331164 hasConceptScore W4250331164C71924100 @default.
• W4250331164 hasIssue "9" @default.
• W4250331164 hasLocation W42503311641 @default.
• W4250331164 hasLocation W42503311642 @default.
• W4250331164 hasOpenAccess W4250331164 @default.
• W4250331164 hasPrimaryLocation W42503311641 @default.
• W4250331164 hasRelatedWork W1506200166 @default.
• W4250331164 hasRelatedWork W1995515455 @default.
• W4250331164 hasRelatedWork W2039318446 @default.
• W4250331164 hasRelatedWork W2048182022 @default.
• W4250331164 hasRelatedWork W2080531066 @default.
• W4250331164 hasRelatedWork W2748952813 @default.
• W4250331164 hasRelatedWork W2899084033 @default.
• W4250331164 hasRelatedWork W3031052312 @default.
• W4250331164 hasRelatedWork W3032375762 @default.
• W4250331164 hasRelatedWork W3108674512 @default.
• W4250331164 hasVolume "28" @default.
• W4250331164 isParatext "false" @default.
• W4250331164 isRetracted "false" @default.
• W4250331164 workType "article" @default.